Dupont Capital Management Corp Raises Position in ANI Pharmaceuticals Inc (ANIP)

Dupont Capital Management Corp boosted its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 113.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,251 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,684 shares during the period. Dupont Capital Management Corp owned 0.16% of ANI Pharmaceuticals worth $1,176,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ANIP. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 91.1% in the second quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock worth $15,878,000 after buying an additional 161,743 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of ANI Pharmaceuticals by 868.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock worth $5,404,000 after purchasing an additional 94,002 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after purchasing an additional 35,722 shares during the last quarter. Cadence Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 422.2% during the 3rd quarter. Cadence Capital Management LLC now owns 33,402 shares of the specialty pharmaceutical company’s stock worth $1,753,000 after purchasing an additional 27,005 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in shares of ANI Pharmaceuticals by 85.5% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 54,900 shares of the specialty pharmaceutical company’s stock worth $2,882,000 after purchasing an additional 25,300 shares during the last quarter. 53.51% of the stock is owned by institutional investors.

Shares of ANI Pharmaceuticals Inc (NASDAQ ANIP) traded up $0.41 on Thursday, reaching $58.92. The company had a trading volume of 111,600 shares, compared to its average volume of 116,309. ANI Pharmaceuticals Inc has a 1 year low of $42.23 and a 1 year high of $74.70. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $681.82, a price-to-earnings ratio of 92.55 and a beta of 2.79.

Several research firms recently weighed in on ANIP. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, December 9th. Zacks Investment Research cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $71.00.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/15/dupont-capital-management-corp-raises-position-in-ani-pharmaceuticals-inc-anip.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply